Back to Continuing Education

Want to buy for someone else? You can purchase a token at check out.

Overview
Goals and Outcomes
Details
Accreditations
Overview
Overview
To provide nurses with information about necrotizing fasciitis and the pathogens associated with the disease.
Goals and Outcomes
Goals and Learning Outcomes
Necrotizing fasciitis (NF), also referred to as necrotizing soft tissue infections in the literature, is a sudden, devastating, life-threatening infection of the subcutaneous tissue that spreads rapidly along the fascial planes causing vascular occlusion, ischemia, and tissue necrosis. The infection is usually, but not always, preceded by blunt trauma or a penetrating soft tissue injury through which bacteria are introduced into the subcutaneous tissue. When toxins are released into circulation, they produce a systemic inflammatory response that can then progress to septic shock, multiple organ failure, and death. With fulminating NF, multiple organ failure and death can occur within the first 24 hours of infection. The devastating and rapid progression of necrotizing fasciitis requires nurses to be well educated about its early symptoms and risk factors so they can recognize the condition and participate in assessing and treating the patient.

After taking this course, you should be able to:

  • Describe the early clinical signs and pathology of necrotizing fasciitis
  • Explain the four types of necrotizing fasciitis and the risk factors and organisms associated with each
  • Discuss the diagnosis and treatment for necrotizing fasciitis and explain why antibiotics, by themselves, don’t work
  • Describe the early clinical signs and pathology of necrotizing fasciitis.
  • Explain the four types of necrotizing fasciitis and the risk factors and organisms associated with each.
  • Discuss the diagnosis and treatment for necrotizing fasciitis and explain why antibiotics, by themselves, do not work.

Course Termination Date: 12/31/23

Content Expiration Date: 09/11/22

Course Originally Released On: 05/01/19
Details
Course Details

Course Originally Released on : 5/1/2019

REL-ACU-0-CE687

Course Author

Barbara Barzoloski-O'Connor

MSN, RN, CIC

Vickie Moore

B.S. Laboratory Science, MA

Connie C. Chettle

MS, MPH, RN

Accreditations
Accreditations

NURSES
In support of improving patient care, Relias LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Provider approved by the California Board of Registered Nursing, CEP#13791

Accreditations imageAccreditations image

Disclaimer: Not all courses will provide California Board of Registered Nursing approval. Per California Assembly Bill No. 241, continuing education courses related to direct patient care shall address at least one or a combination of the following:(1) Examples of how implicit bias affects perceptions and treatment decisions of licensees, leading to disparities in health outcomes; or (2) Strategies to address how unintended biases in decision-making may contribute to health care disparities by shaping behavior and producing differences in medical treatment along lines of race, ethnicity, gender identity, sexual orientation, age, socioeconomic status, or other characteristics.

CEBroker
Relias LLC reports to CEBroker for the following boards (Provider # 50-1489): Arkansas State Board Of Nursing, District Of Columbia Board Of Nursing, Florida Board Of Nursing, Georgia Board Of Nursing, New Mexico Board Of Nursing, South Carolina Board Of Nursing and West Virginia Board Of Examiners For Registered Professional Nurses
Please check the licenses/certifications section under my account (after logging in) to make sure you have entered a valid license number. This information is required for correct reporting of your course completions to CE Broker.

Disclosures
None of the planners/faculty, unless otherwise noted, for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.